AstraZeneca acquires Omniose
AstraZeneca has acquired Omniose, an early-stage biotechnology firm developing vaccines against serious bacterial infections.
The acquisition follows a three-year exclusive research collaboration between the companies.
“Omniose’s bioconjugation platform represents a differentiated approach to engineering conjugate vaccines and strengthens our ability to develop novel vaccines against serious bacterial infections,” said Benjamin Moutier, AstraZeneca’s senior vice president of infectious disease, to Reuters.
Financial terms of the deal were not disclosed
Published: November 16, 2026
